

BIOSTOCK PUBLISHES ARTICLE ABOUT THE POSITIVE PRE-CLINICAL RESULTS AND COMING MILESTONE FOR PROLIGHT DIAGNOSTICS IN Q2

Prolight's CSO reflects on positive pre-clinical results and looks ahead to the next key milestone in Q2:

Read the article here: <https://biostock.se/2025/05/prolights-cso-reflects-on-positive-pre-clinical-results-and-looks-ahead-to-key-milestone-in-q2/>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2